Delivery Order SPE2DB25D3003-SPE2DB25FPXCK
- Not listed
- The Defense Logistics Agency awarded a $10,809.15 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The contract carries no set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $5,128.38. This firm fixed-price, non-set-aside contract is classified as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $21,408.43 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on September 4, 2025, with an ultimate completion date of September 5, 2025. The contract employs firm fixed price terms with no set-aside designation, indicating competitive award status. Performance will be conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under the...
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $37,144.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price delivery order, awarded on August 20, 2025, with a completion date of August 21, 2025, represents a non-competitive award under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $9,481.08 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $13,364.64 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injections on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price, non-competitive delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's facility...
- SPE2DB25D3003Indefinite Delivery Contract
- SPE2DB25D3003-SPE2DB25FPXCKDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $53,697.89. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for ultimate completion by September 9, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor under this delivery order. The contract is a child agreement issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical procurement services to federal defense and healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering a wide range of pharmaceutical products across multiple therapeutic domains, including specialty medications, vaccines, and medical devices to support military personnel and veteran healthcare needs. This delivery order for Dupixent, a biologic medication used for immunological conditions, reflects the company's ongoing role as a key vendor within the DLA Medical Supply Chain, supporting the healthcare requirements of the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $53.7k | 9/8/25 |